Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Will Merck Stock Rise After Its Q2 Results?
06:00am, Monday, 25'th Jul 2022
Merck (NYSE: MRK) is scheduled to report its Q2 2022 results on Thursday, July 28. We expect the company to have a robust Q2, with revenue falling in-line and earnings expected to be slightly above th
Three Watchlist Stocks to Capitalize on Sector Rotation
01:00am, Saturday, 23'rd Jul 2022
Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into.
Merck Q2 Preview: Double-Digit Earnings Growth in Store?
05:08pm, Friday, 22'nd Jul 2022
Year-to-date, Merck shares are well in the green, increasing nearly 20% in value and easily outperforming its Zacks Industry.
2nd-Quarter Earnings Results Could Impact Drug Company Shares
04:58pm, Friday, 22'nd Jul 2022
The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-ti
Blue-Chip Drug Stock Could Keep Lapping Broader Market
08:00am, Friday, 22'nd Jul 2022
Schaeffer's Investment Research was built from scratch on Bernie Schaeffer's vision of providing accessible professional-grade trading information to retail traders.
Healthcare ETFs in Focus Ahead of Q2 Earnings
01:14pm, Thursday, 21'st Jul 2022
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfo
Merck's (MRK) Keytruda Head and Neck Cancer Study Fails
10:07am, Thursday, 21'st Jul 2022
Merck's (MRK) phase III KEYNOTE-412 study, evaluating Keytruda in earlier stages of unresected locally advanced head and neck squamous cell carcinoma, disappoints.
I'm Buying These 3 Resilient Stocks During a Bear Market
06:06am, Thursday, 21'st Jul 2022
These companies' recent bullishness comes as no surprise once you hear the backstories.
Long-Term Revenue Projections Suggest Merck Will Survive, Even Thrive, After Keytruda LOE
02:10pm, Wednesday, 20'th Jul 2022
Merck's share price has been climbing, up ~13% since my last bullish note. The company began the year strongly, with $15.7bn revenues generated in Q122, and the FY22 forecast is for an 18% uplift to ~
Merck's Keytruda fails head and neck cancer trial
07:09am, Wednesday, 20'th Jul 2022
Merck & Co Inc said on Wednesday its cancer therapy Keytruda failed to meet the main goal of a late-stage trial testing it in patients with head and neck cancer.
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study
01:15pm, Tuesday, 19'th Jul 2022
Merck & Co Inc (NYSE: MRK) will stop for futility the Phase 3 LYNK-003 trial of Lynparza with or without bevacizumab for unresectable or metastatic colorectal cancer who have not progressed followi
Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood
08:06pm, Monday, 18'th Jul 2022
JNJ Management expects relatively consistent growth for the rest of the year.
Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say
10:33pm, Friday, 15'th Jul 2022 MarketWatch
Merck & Co.’s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant’s earnings later this month, though the talks remain on track, according to peo
Merck deal for Seagen unlikely to be finalized ahead of earnings later this month, sources say
06:33pm, Friday, 15'th Jul 2022
Merck & Co.'s roughly $40 billion deal for Seagen Inc. is unlikely to be finalized ahead of the pharmaceutical giant's earnings later this month, though the talks remain on track, according to people
UnitedHealth Group (UNH) Q2 Earnings Beat, Hikes '22 EPS View
03:34pm, Friday, 15'th Jul 2022 Zacks Investment Research
UnitedHealth Group's (UNH) second-quarter results gain from revenue growth stemming from solid segmental contributions and membership growth. A raised 2022 EPS view remains noteworthy.
